|
In a lawsuit filed in the US, Novo alleged that Lilly’s campaign was designed to mislead consumers on “comparative efficacy” of drug brands.
|
 |
|
Clinical data supporting the expanded approval come from the Phase I/II open-label multi-centre BUR-CL207 trial.
|
|
|
Novartis continues to navigate a decisive period as newer portfolio assets start to offset patent pressures.
|
|
|
Under the collaboration, Cellares will adapt the PPL-001 manufacturing process for its Cell Shuttle platform.
|
|
|
While progress has been made to influence the treatment landscape of Alzheimer’s disease, gaps to widespread therapeutic availability and imaging remain.
|
|
